New combo aims to tame Chemo's nerve damage in bladder cancer

NCT ID NCT07484022

Recruiting now Symptom relief Sponsor: Generate Biomedicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an investigational drug called GB-4362 given alongside standard treatments (enfortumab vedotin and pembrolizumab) for adults with advanced or metastatic urothelial cancer. The goal is to see if GB-4362 can safely neutralize a chemotherapy byproduct that often causes nerve damage. About 37 participants will be enrolled to check safety and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

peripheral nervous system disorder transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED UROTHELIAL CANCER METASTATIC UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

COH Atlanta
RECRUITING

Tucker, Georgia, 30084, United States
COH Chicago
RECRUITING

Zion, Illinois, 60099, United States
COH Lennar
RECRUITING

Irvine, California, 92618, United States
City of Hope
RECRUITING

Duarte, California, 91010, United States
MDACC
RECRUITING

Houston, Texas, 77030, United States
MSK
RECRUITING

New York, New York, 10065, United States
Orlando Health
RECRUITING

Orlando, Florida, 32806, United States
Rutgers
RECRUITING

New Brunswick, New Jersey, 22908, United States
Start New York, LLC
RECRUITING

Lake Success, New York, 11042, United States
The University of Virgina
RECRUITING

Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.